Antivirals with Activity Against Monkeypox: A Clinically Oriented Review

Resource type
Journal Article
Authors/contributors
Title
Antivirals with Activity Against Monkeypox: A Clinically Oriented Review
Abstract
Monkeypox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore three antiviral agents with activity against monkeypox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific activity against orthopoxviruses, and inhibits the formation of the extracellular enveloped virus necessary for cell-to-cell transmission. For each agent, we review basic pharmacology, data from animal models and reported experience in human patients.
Publication
Clinical Infectious Diseases
Date
2022-07-29
Pages
ciac622
Journal Abbr
Clinical Infectious Diseases
Accessed
8/6/22, 10:36 AM
ISSN
1058-4838
Short Title
Antivirals with Activity Against Monkeypox
Library Catalog
Silverchair
Citation
Siegrist, E. A., & Sassine, J. (2022). Antivirals with Activity Against Monkeypox: A Clinically Oriented Review. Clinical Infectious Diseases, ciac622. https://doi.org/10.1093/cid/ciac622
ORGANISMS
Link to this record